Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection
Archive ouverte
Bachelard, Antoine | Le Hingrat, Quentin | Ferré, Valentine-Marie | Lê, Minh | Peytavin, Gilles | Damond, Florence | Charpentier, Charlotte | Fremont Goudot, Guillemette | Goupil de Bouille, Jeanne | Lariven, Sylvie | Delobel, Pierre | Yazdanpanah, Yazdan | Descamps, Diane | Matheron, Sophie | Ghosn, Jade | Appay, Victor | Autran, Brigitte | Besseghir, Amel | Couffin-Cardiergues, Sandrine | Birklé, Chloé | Brun-Vezinet, Françoise | Chêne, Geneviève | Cheynier, Rémi | Collin, Fidéline | Eholie, Serge | Ekouvie, Didier | Faguard, Catherine | Lebrasseur, Delphine | Longobardi, Julie | Marchand, Lucie | Muller-Trutwin, Michaela | Ozanne, Alexandra | Petrov-Sanchez, Ventzislava | Roy, Céline | Saez-Cirion, Asier | Simon, François | Wittkop, Linda | Meyohas, Marie Caroline | Lacombe, Karine | Salmon, Dominique | Rami, Agathe | Pialoux, Gilles | Tubiana, Roland | de Truchis, Pierrre | Khuong-Josses, Marie-Aude | Derradji, Ouda | Troisvallet, Didier | Timsit, Julie | Lascaux, Anne-Sophie | Jeantils, Vincent | Bouchaud, Olivier | Patey, Olivier | Caraux-Paz, Pauline | Goujard, Cécile | Gérard, Laurence | Mortier, Emmanuel | Froguel, Eric | Welker, Yves | Daneluzzi, Vincent | Genet, Philippe | Leprêtre, Annie | Zucman, David | Force, Gilles | Coutellier-Simon, Anne | Deleuze, Jean | Weiss, Laurence | Garrait, Valérie | Colin, Hélène Masson | Blum, Laurent | Lelièvre, Pr Jean-Daniel | Dulioust, Anne | Perrone, Véronique | Billy, Christophe | Winter, Cécile | Aupérin, Isabelle | Torre, Iram La | Molina, Jean-Michel | Brunet, Patrick | Lamy, Sylvia | Devidas, Alain | Chabrol, Amélie | Rouveix, Elisabeth | Kernbaum, Serge | Duvivier, Claudine | Bouldouyre, Marie-Anne | Bodard, Loïc | Imbert, Patrick | Rapp, Christophe | Boué, François | Uludag, Agnès | Chaix, Fabrice | Son, Olivia | Viard, Jean-Paul | Duval, Xavier | Belan, Alix Greder | Grégoire, Valérie | Beck-Wirth, Genviève | Raffi, François | Drobacheff, Christine | Chirouze, Catherine | Allègre, Thierry | Verdon, Renaud | Poizot-Martin, Isabelle | Daniel, Corinne | Machado, Moise | Lecapitaine, Anne-Lise | Marchou, Pr Bruno | Bernard, Louis | Debab, Yasmine | Leclercq, Pascale | Julien, Joelle | Moreau, Jacques | Ravaux, Isabelle | Arvieux, Cédric | Michaud, Christophe | Makhloufi, Djamila | Lemoal, Gwenael | Arsac, Philippe | Prazuck, Thierry | Lafeuillade, Alain | Martha, Benoit | Perré, Philippe | Ajana, Faiza | Morlat, Philippe | Brottier, Elisabeth | Dupon, Michel | Neau, Didier | Pellegrin, Jean-Luc | Raymond, Isabelle | Montagne, Nathalie | May, Thierry | Wille, Heidi | Douadi, Youssef | Reynes, Jacques | Schmit, Jean-Louis | Rouger, Chrisitne | Berger, Jean-Luc | Poinsignon, Yves | Jacomet, Christiane | Piroth, Lionel | Rosenthal, Eric | Garipuy, Daniel | Michaud, Martin | Riché, Agnes | Du Clary, François Prevoteau | Naqvi, Alica | Gaillat, Jacques | Rey, David | Abino, François | Mercié, Patrick | Roger, Pierre-Marie | Aïssi, Emmanuelle | Chennebault, Jean-Marie | Liné, Dominique | Randrianasolo, Narimamy | Merle, Catherine | Granet, Patricia | Caunègre, Laurence | Cotte, Laurent | Boileau, Laurent | Euzen, Jean-Batiste | Perfezou, Pascale | Lefebvre, Nicolas | Talarmin, Jean-Philippe | Pavel, Simona | Ponceau, Bénédicte | Saison, Julien | Sotto, Albert | Laureillard, Didier | Vandendriessche, Anne | Darasteanu, Iuliana | Mecheri, Manal | Saidi, Tounes | Sangaré, Ami | Chaghil-Boissière, Nathalie | Conte, Valérie | Dembelé, Mohamed | Khalil, Youssra | Pallier, Maxime | Pinoges, Loretxu | Chalal, Solaya | Oualit, Lynda | Becam, Leia | Cirscota, Sophie | Lascoux, Carine | Leger, Lydia | Legoff, Marie | Pellegrin, Isabelle | Youssef, Leen | Brun-Vézinet, Françoise | Pancino, Gianfranco | Hosmalin, Anne | Vieillard, Vincent
Edité par
CCSD ; Oxford University Press (OUP) -
International audience.
Abstract We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
